Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1).
Janus kinase (JAK) 3-deficient mice were not able to reject allogeneic islet allografts. The JAK3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (CAS 202475-60-3, JANEX-1, WHI-P131) prevented the rejection of islet allografts in mice with a normal JAK3 expression status. The combination of JANEX-1 and cyclosporin A (CAS 59865-13-3) was more effective than either agent alone.
Cetkovic-Cvrlje
Marina
M
Department of Immunology, Parker Hughes Institute and Parker Hughes Cancer Center, St. Paul, MN, USA.
Dragt
Angela L
AL
Uckun
Fatih M
FM
D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000601:surgery*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D053616:Janus Kinase 3; D008285:Major Histocompatibility Complex / Q000235:genetics; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D011799:Quinazolines; C116180:WHI P131; D016572:Cyclosporine; D011505:Protein-Tyrosine Kinases; C507935:Jak3 protein, mouse; D053616:Janus Kinase 3